John Newman
Stock Analyst at Canaccord Genuity
(1.31)
# 3,223
Out of 4,814 analysts
87
Total ratings
35.14%
Success rate
-13.67%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Hold | $170 → $150 | $563.16 | -73.36% | 17 | Apr 17, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.45 | +865.52% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $98.76 | +73.59% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $6.16 | +175.97% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.16 | +589.66% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $4.55 | +449.45% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $10 | $0.37 | +2,602.70% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $11.60 | +81.11% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $61.99 | +85.51% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.53 | +1,421.49% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $43.00 | +55.81% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $10.40 | +313.46% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $4.98 | +120.88% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.56 | +791.27% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $27.66 | +59.07% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,720 → $400 | $4.15 | +9,538.55% | 4 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $7.44 | +2,858.98% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $13.74 | +176.56% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $2.19 | +1,135.70% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $7.76 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Hold
Price Target: $170 → $150
Current: $563.16
Upside: -73.36%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.45
Upside: +865.52%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $98.76
Upside: +73.59%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $6.16
Upside: +175.97%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.16
Upside: +589.66%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $4.55
Upside: +449.45%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $10
Current: $0.37
Upside: +2,602.70%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $11.60
Upside: +81.11%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $61.99
Upside: +85.51%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.53
Upside: +1,421.49%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $43.00
Upside: +55.81%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $10.40
Upside: +313.46%
May 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $4.98
Upside: +120.88%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.56
Upside: +791.27%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $27.66
Upside: +59.07%
Aug 10, 2021
Downgrades: Hold
Price Target: $1,720 → $400
Current: $4.15
Upside: +9,538.55%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $7.44
Upside: +2,858.98%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $13.74
Upside: +176.56%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $2.19
Upside: +1,135.70%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $7.76
Upside: -